



A monthly report summarizing life science transactions in Washington State.

BY THE NUMBERS: (YTD) **73** TRANSACTIONS **TOTALING OVER \$4.32B**

Deals Per Sector



Disclosed Funding By Sector



JULY TOP TRANSACTIONS

Icosavax, a Seattle-based biotech firm, surged more than 200% on its first day of trading. The company, a spin-out from the University of Washington's Institute for Protein Design, is developing vaccines to resemble naturally occurring viruses ([GeekWire](#)).

AbSci, which is developing technologies to accelerate drug discovery, is riding a wave of biotech IPOs. By mid-2021, 49 biotechs had gone public, according to Biopharma Dive — a faster pace than 2020, which itself was a record year ([GeekWire](#)).

Shape Therapeutics, a Seattle preclinical stage biotech company developing RNA editing and gene therapy technologies, has raised \$112M. The company is working on improving AAV vectors, a gene therapy delivery system that is the backbone of FDA-approved gene therapies for spinal muscular atrophy and a rare vision disease ([GeekWire](#)).

OTHER TRENDS & HIGHLIGHTS

Seattle's Life Science Industry's venture capital funding grew 266% in the first quarter of 2021 compared with Q1 2020, making Seattle the fastest-growing major market in the country, according to a CBRE report ([Puget Sound Business Journal](#)).

EchoNous, a Redmond-based medical technology company, announced it raised \$60M in a funding round led by Kennedy Lewis Investment Management. They will use the money to commercialize its 8-ounce, handheld tool that enables heart, lung and abdomen scans ([Puget Sound Business Journal](#)).

Selkirk Pharma, has designs on a \$90M headquarters and production plant in Spokane, Washington. Selkirk plans to kit out its 145,000-square-foot injectables factory with isolator-based filling systems and electronic batch records. The site will handle both clinical and commercial production ([FiercePharma](#)).

Lyell Immunopharma launches IPO raising \$425M. Lyell is headquartered in the Bay Area but with University of Washington roots and major operations in Seattle and Bothell ([Cooley](#)).

TRANSACTIONS

Date	Company	Sector	Type	Amount	Location
01-Jul-2021	Aminex Therapeutics	Biotech	Later Stage VC	\$9,160,000	Kenmore
06-Jul-2021	Cyrus Biotechnology	Digital Health	Later Stage VC	\$10,203,000	Seattle
12-Jul-2021	Kineta	Biotech	Later Stage VC	\$11,810,000	Seattle
13-Jul-2021	Truveta	Digital Health	Early Stage VC	\$95,000,000	Seattle
15-Jul-2021	Modulus Therapeutics	Biotech	Seed Round	\$3,780,000	Seattle
15-Jul-2021	ShapeTX	Biotech	Early Stage VC	\$112,000,000	Seattle
16-Jul-2021	Soovu	Medtech	Later Stage VC	\$5,830,000	Seattle
22-Jul-2021	AbSci	Biotech	IPO	\$200,000,000	Vancouver
22-Jul-2021	Arzeda	Biotech	Later Stage VC	\$25,730,000	Seattle
27-Jul-2021	Thrive Biosafety	Medtech	Equity Crowdfunding	\$10,000	Spokane
29-Jul-2021	Icosavax	Biotech	IPO	\$182,000,000	Seattle
30-Jul-2021	Proprio	Medtech	Later Stage VC	\$5,000,000	Seattle
July Total (disclosed transactions):				\$660,550,000	
June Total (disclosed transactions):				\$572,110,000	
May Total (disclosed transactions):				\$14,530,000	
April Total (disclosed transactions):				\$841,190,000	
March Total (disclosed transactions):				\$1,089,960,000	
February Total (disclosed transactions):				\$666,580,000	
January Total (disclosed transactions):				\$478,070,000	